Global Anticoagulants Market Analysis, Trends and Forecast until 2022

The report also provides an analysis of injectable and oral anticoagulants available in the market. Details of Lovenox, Arixtra, Xarelto, Eliquis, Pradaxa and Savaysa has been provided in the report in terms of their global sales. A brief analysis of the US anticoagulants market has also been provided in terms of value and sales of top four oral anticoagulant drugs in the region.Furthermore, the report also assesses the key opportunities available in the market and outline the market dynamics that are and will be accountable for growth of the industry. Growth of the global anticoagulants market has also been forecasted for the period 2018-2022, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.

Bayer, BMS/Pfizer, Boehringher Ingelheim and Daiichi Sankyo are some of the key players operating in the global anticoagulants market, whose company profiling has been done in the report. This segment summarizes business overview, financial overview and the business strategies of the companies.

Company Coverage

Bayer
BMS/Pfizer
Boehringher Ingelheim
Daiichi Sankyo

Regional Coverage

The US

Browse Full Report with TOC-https://www.marketresearchhub.com/report/global-anticoagulants-market-2018-2022-edition-report.html

Executive Summary

Anticoagulants which are also known as blood thinners are drugs that are prescribed to prevent blood from clotting or stop existing clots from getting larger. The drugs prevent harmful clots forming in heart, veins or arteries. Formation of clots in the blood can lead to heart attack or stroke. These drugs are used to treat strokes, myocardial infarctions, pulmonary embolisms, disseminated intravascular coagulation (DIC) and deep vein thrombosis (DVT)- all potentially life-threatening conditions. Anticoagulants work by interrupting the process involved in the formation of blood clots.

The most commonly prescribed anticoagulant is Warfarin. Newer types of anticoagulants are also available and are becoming increasingly common. These include rivaroxaban (Xarelto), dabigatran (Pradaxa), apixaban (Eliquis), and edoxaban (Savaysa/Lixiana). Warfarin and the newer alternatives are taken as tablets or capsules. There’s also an anticoagulant called heparin that can be given by injection.

The global anticoagulants market has increased over the years and is expected to grow in the next four years i.e. 2018-2022, particularly due to development of novel oral anticoagulants (NOACs). The global anticoagulants market is supported by various growth drivers such as growing aging population, rising prevalence of coagulant disorders, increasing demand for NOACs, rising awareness about anticoagulants, etc. Yet, the market faces some challenges which are obstructing the growth of the market. Some of the challenges are stringent regulations from regulatory bodies, high cost of oral anticoagulants, major side-effects associated with the drugs, etc.